204 related articles for article (PubMed ID: 22302271)
41. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ; Semino-Mora C; Friedline CJ; Liu H; Bodi KL; McAvoy TJ; Francis J; Nieroda C; Sardi A; Dubois A; Lazinski DW; Camilli A; Testerman TL; Merrell DS
Orphanet J Rare Dis; 2013 Jul; 8():105. PubMed ID: 23844722
[TBL] [Abstract][Full Text] [Related]
42. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
43. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
44. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
45. Mucin as a therapeutic target in pseudomyxoma peritonei.
Choudry HA; O'Malley ME; Guo ZS; Zeh HJ; Bartlett DL
J Surg Oncol; 2012 Dec; 106(7):911-7. PubMed ID: 22585683
[TBL] [Abstract][Full Text] [Related]
46. Two independent primary mucinous tumors involving the appendix and ovary accompanied with acellular pseudomyxoma peritonei.
Zhou F; Chen X; Li Y; Huang L
Int J Clin Exp Pathol; 2015; 8(9):11831-4. PubMed ID: 26617936
[TBL] [Abstract][Full Text] [Related]
47. Establishment and characterization of NCC-PMP2-C1: a novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells.
Noguchi R; Yoshimatsu Y; Sin Y; Ono T; Tsuchiya R; Yoshida H; Kiyono T; Yonemura Y; Kondo T
Hum Cell; 2024 Mar; 37(2):511-522. PubMed ID: 38143259
[TBL] [Abstract][Full Text] [Related]
48. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
49. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
50. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms.
Young RH
Semin Diagn Pathol; 2004 May; 21(2):134-50. PubMed ID: 15807473
[TBL] [Abstract][Full Text] [Related]
51. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.
Saarinen L; Nummela P; Leinonen H; Heiskanen A; Thiel A; Haglund C; Lepistö A; Satomaa T; Hautaniemi S; Ristimäki A
Mol Cell Proteomics; 2018 Nov; 17(11):2107-2118. PubMed ID: 30072579
[TBL] [Abstract][Full Text] [Related]
52. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
53. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
54. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".
Ronnett BM; Zahn CM; Kurman RJ; Kass ME; Sugarbaker PH; Shmookler BM
Am J Surg Pathol; 1995 Dec; 19(12):1390-408. PubMed ID: 7503361
[TBL] [Abstract][Full Text] [Related]
55. A case of appendiceal cancer metastatic to the stomach with pseudomyxoma peritonei.
Miyashita T; Hoshino E; Imamura T; Okinaga K; Akaoka I; Miyashita H
J Gastroenterol; 1994 Feb; 29(1):71-5. PubMed ID: 7515309
[TBL] [Abstract][Full Text] [Related]
56. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962
[TBL] [Abstract][Full Text] [Related]
57. A unique presentation of superinfected pseudomyxoma peritonei secondary to a low-grade appendiceal mucinous neoplasm.
Sullivan BJ; Bolton N; Sarpel U; Magge D
World J Surg Oncol; 2019 Feb; 17(1):34. PubMed ID: 30777068
[TBL] [Abstract][Full Text] [Related]
58. Pulmonary metastases in pseudomyxoma peritonei syndrome.
Mortman KD; Sugarbaker PA; Shmookler BM; DeGuzman VC; Soberman MS
Ann Thorac Surg; 1997 Nov; 64(5):1434-6. PubMed ID: 9386716
[TBL] [Abstract][Full Text] [Related]
59. Suppression of mucin 2 enhances the proliferation and invasion of LS174T human colorectal cancer cells.
Bu X; Li L; Li N; Tian X; Huang P
Cell Biol Int; 2011 Nov; 35(11):1121-9. PubMed ID: 21605079
[TBL] [Abstract][Full Text] [Related]
60. Orthotopic animal model of pseudomyxoma peritonei: An in vivo model to test anti-angiogenic drug effects.
Dohan A; Lousquy R; Eveno C; Goere D; Broqueres-You D; Kaci R; Lehmann-Che J; Launay JM; Soyer P; Bonnin P; Pocard M
Am J Pathol; 2014 Jul; 184(7):1920-9. PubMed ID: 24814606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
